Clicky

Biocartis Group NV(BIOGF)

Description: Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.


Keywords: Medicine Biotechnology Clinical Medicine Oncology Molecular Diagnostics Medical Genetics Epidermal Growth Factor Receptor Oncogenes Diagnostic Solutions Kras Oncology Therapies Idylla Idylla Braf Idylla Platform

Home Page: www.biocartis.com

Generaal de Wittelaan 11 B
Mechelen, 2800
Belgium
Phone: 32 1 563 20 00


Officers

Name Title
Mr. Herman Verrelst CEO & Exec. Director
Mr. Jean-Marc Roelandt Chief Financial Officer
Mr. Piet Houwen Chief Operating Officer
Mr. Benoit Devogelaere Chief Technology Officer
Mr. Geert Maertens Ph.D. Chairman of Scientific Advisory Board & Chief Scientific Officer
Renate Degrave Head of IR & Corp. Communications
Ms. Susy Spruyt Head of People & Organization
Dr. Erwin Sablon Head of R&D and Alliance Management
Mr. Reginald Van Genechten Head of Manufacturing & Supply Chain
Mr. Dirk Zimmermann Global Head of Pharma Collaborations & Partnering

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 1.0367
IPO Date:
Fiscal Year End: December
Full Time Employees: 619
Back to stocks